课题基金 / 基金详情

项目摘要

项目成果

Deepta Bhattacharya的其他基金

相似基金

相关文献

中文摘要
翻译
从自身免疫性疾病患者中分离出的抗体的自我反应性通常是由体细胞突变所致。事实上,免疫球蛋白基因回复到生殖系序列通常会消除对自身抗原的反应性。这些数据表明,许多自身反应性B细胞来源于生发中心反应,在生发中心反应中,免疫球蛋白可变基因发生体细胞超突变。自我反应性B细胞在早期发育过程中被消除的机制是众所周知的。相比之下,对于健康个体中体细胞突变诱导的自我反应性通常是如何防止的,以及这些途径中哪些在自身免疫性疾病患者中失败,人们知之甚少。在这项建议中,我们将确定B细胞受体(BCR)信号下游的生存途径,以及允许自身反应性B细胞存活的CD4+T细胞帮助。
英文摘要
Self-reactivity in antibodies isolated from patients with autoimmune disorders is often imparted by somatic mutations. Indeed, reversion of immunoglobulin genes to germ line sequences typically eliminates reactivity against self-antigens. These data suggest that many autoreactive B cells are derived from the germinal center reaction, in which somatic hypermutation of immunoglobulin variable genes occurs. The mechanisms by which self-reactive B cells are eliminated during early development are well-understood. In contrast, very little is known about how somatic mutation-induced self-reactivity is normally prevented in healthy individuals, and which of these pathways fail in patients with autoimmune disorders. In this proposal, we will identify the survival pathways downstream of B cell receptor (BCR) signals and CD4+ T cell help that allow autoreactive B cells to survive.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
GLUCOSE AND AMINO ACID CATABOLISM IN PLASMA CELL BIOLOGY
  • 批准号:
    10530743
  • 项目类别:
  • 资助金额:
    $7.5万
  • 财政年份:
    2017
  • 负责人:
    Deepta Bhattacharya
  • 依托单位:
GLUCOSE AND AMINO ACID CATABOLISM IN PLASMA CELL BIOLOGY
  • 批准号:
    10305650
  • 项目类别:
  • 资助金额:
    $46.01万
  • 财政年份:
    2017
  • 负责人:
    Deepta Bhattacharya
  • 依托单位:
GLUCOSE AND AMINO ACID CATABOLISM IN PLASMA CELL BIOLOGY
  • 批准号:
    10476036
  • 项目类别:
  • 资助金额:
    $2.22万
  • 财政年份:
    2017
  • 负责人:
    Deepta Bhattacharya
  • 依托单位:
GLUCOSE AND AMINO ACID CATABOLISM IN PLASMA CELL BIOLOGY
  • 批准号:
    10059162
  • 项目类别:
  • 资助金额:
    $46.01万
  • 财政年份:
    2017
  • 负责人:
    Deepta Bhattacharya
  • 依托单位:
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2022
  • 负责人:
    王亚伟
  • 依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究